verifi® Prenatal Test Advantage
Verinata’s verifi® test has some key advantages that make it the first choice among clinicians.
- Superior Technology: Only clinical evidence showing across-the-genome analysis in a real-world population
- Comprehensive Analysis: First test to offer option of comprehensive sex chromosome analysis
- Informative Results: Helpful classification that can indicate borderline results
The verifi® prenatal test leverages the power of Massively Parallel Sequencing (MPS) with a highly optimized algorithm to provide clear, informative results. The SAFeR™ method calculates a Normalized Chromosome Value (NCV) for each chromosome, which significantly reduces data variation caused by GC content, sample-to-sample and run-to-run variations and other factors. By pre-determining the most optimal reference chromosomes in an empirical analysis, no post-hoc correction factors or patient-specific information are necessary.
The verifi® test with SAFeR™ provides definitive results. It is not a risk score, and it is not dependent on maternal age, maternal weight or gestational age (after 10 weeks). Unlike SNP-based tests, the verifi® test is not affected by ethnicity.
Safe and Effective Classification
All testing methods can encounter borderline results. The verifi® prenatal test applies a safe and effective classification to these results, employing a dual threshold with a third result type: “Aneuploidy Suspected (Borderline Value).”
In a large-scale study population, approximately 0.2–0.6% of results were classified as “Aneuploidy Suspected” for each particular chromosome.* Both aneuploid and euploid samples can receive this result, which gives an indication that chances of a false positive are higher. Both “Aneuploidy Detected” and “Aneuploidy Suspected” results should be confirmed with an invasive procedure.
*Data on file
Our Client Services group is on site and readily available along with certified genetic counselors to provide knowledgeable, timely support.
Call Verinata at: